35 Although these CVOTs were not specifically powered to detect differences in HF outcomes, they provided the first valuable signs of the benefit of GLP-1RAs in patients with HF
Cells at passages 35 were used for subsequent experiments
Essential compliance elements include: Proper labeling of every vial with concentration, lot, prep date, and operator
In mouse models of highfat dietinduced liver steatosis, it significantly inhibits hepatic NNMT activity, reduces NAM methylation, increases NAD+ and SAM levels, enhances mitochondrial fatty acid oxidation, reduces hepatic triglyceride and lipid accumulation, lowers lipotoxicity markers (e.g., malondialdehyde, transaminases), improves hepatocellular injury, and reverses steatosis
"Market sizing for GLP-1 expanded indications." [30] Eli Lilly
One the box, it's 700mg while on the blister pack it's 650mg